No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.

Source: Clinical Infectious Diseases - October 13, 2016 Category: Infectious Diseases Authors: Sulkowski, M. S., Chuang, W.-L., Kao, J.-H., Yang, J. C., Gao, B., Brainard, D. M., Han, K.-H., Gane, E. Tags: BRIEF REPORTS Source Type: research